TOPLINE RESULTS FROM THE ALPINE 2/3 STUDY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 2b TRIAL EVALUATING 3 DOSES OF THE FGF19 ANALOGUE ALDAFERMIN ON LIVER HISTOLOGY IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND STAGE 2 OR 3 FIBROSIS

被引：0

作者：

Harrison, Stephen A. ^{[1
]}

Abdelmalek, Manal F. ^{[2
]}

Neff, Guy W. ^{[3
]}

Gunn, Nadege ^{[1
]}

Guy, Cynthia D. ^{[2
]}

Alkhouri, Naim ^{[4
]}

Bashir, Mustafa ^{[2
]}

Freilich, Bradley ^{[5
]}

Almeda, Jose ^{[6
]}

Knapple, Whitfield ^{[7
]}

Kohli, Anita ^{[4
]}

Khazanchi, Arun ^{[8
]}

Sheikh, Muhammad Y. ^{[9
]}

Leibowitz, Mark ^{[10
]}

Hogan, Reed ^{[11
]}

White, Judith ^{[12
]}

Kayali, Zeid ^{[13
]}

Rinella, Mary E. ^{[14
]}

Siddiqui, Mohammad S. ^{[15
]}

Kipnes, Mark ^{[16
]}

Moussa, Sam E. ^{[17
]}

Ortiz-Lasanta, Grisell ^{[18
]}

Poulos, John ^{[19
]}

Younes, Ziad ^{[20
]}

Bansal, Meena B. ^{[21
]}

Baum, Seth J. ^{[22
]}

Borg, Brian ^{[23
]}

Ruane, Peter J. ^{[24
]}

White, Alexander ^{[25
]}

Merkes, Kevin ^{[26
]}

Rashmee, Patil ^{[27
]}

Thuluvath, Paul J. ^{[28
,29
]}

Gottwald, Mildred ^{[30
]}

Khan, Mujib ^{[30
]}

Chen, Charles ^{[30
]}

Yan, Andrew Z. ^{[30
]}

Melchor-Khan, Liza ^{[30
]}

Chang, William ^{[30
]}

DePaoli, Alex ^{[30
]}

Ling, Lei ^{[30
]}

Lieu, Hsiao ^{[30
]}

机构：

[1] Pinnacle Clin Res, San Antonio, TX USA

[2] Duke Univ, Durham, NC USA

[3] Covenant Res & Clin, LLC, Sarasota, FL USA

[4] Arizona Liver Hlth, Chandler, AZ USA

[5] Kansas City Res Inst, Kansas City, MO USA

[6] Doctors Hosp Renaissance, Edinburg, TX USA

[7] Arkansas Gastroenterol, Hot Springs, AR USA

[8] Florida Res Inst, Bradenton, FL USA

[9] Fresno Clin Res Ctr, Fresno, CA USA

[10] Natl Res Inst, Delhi, NY USA

[11] GI Assoc & Endoscopy Ctr, Wausau, WI USA

[12] Bioclin Res, Princeton, NJ USA

[13] Inland Empire Liver Fdn, Rialto, CA USA

[14] Northwestern Univ, Evanston, IL USA

[15] Virginia Commonwealth Univ, Dept Internal Med, Div Gastroenterol Hepatol & Nutr, Richmond, VA USA

[16] Diabet & Glandular Dis Clin, San Antonio, TX USA

[17] Adobe Clin Res, Tucson, AZ USA

[18] Fdn Invest, San Juan, PR USA

[19] Cumberland Res Assoc, Cumberland, MD USA

[20] Gastro One, Germantown, TN USA

[21] Icahn Sch Med Mt Sinai, Dept Med, Div Liver Dis, New York, NY 10029 USA

[22] Excel Med Clin Trials, Boca Raton, FL USA

[23] Southern Therapy & Adv Res, Madison, NJ USA

[24] Ruane Clinical Res Grp Inc, Los Angeles, CA USA

[25] Progress Med Res, Port Orange, FL USA

[26] Alliance Clin Res, Alliance, OH USA

[27] South Texas Res Inst, Edinburg, TX USA

[28] Mercy Med Ctr, Baltimore, MD USA

[29] Univ Maryland, Sch Med, Baltimore, MD USA

[30] Ngm Biopharmaceut, San Francisco, CA USA

来源：

HEPATOLOGY | 2021年 / 74卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：5A / 6A

页数：2

共 50 条

[41] Efficacy and safety of the oral JAK3/TEC inhibitor ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO Phase 2b/3 randomized, double-blind, placebo-controlled trial
Hordinsky, Maria K.
Hebert, Adelaide
Gooderham, Melinda
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB51 - AB51
[42] Efficacy and Safety of Inosine Pranobex in COVID-19 Patients: A Multicenter Phase 3 Randomized Double-Blind, Placebo-Controlled Trial
Jayanthi, C. R.
Swain, Ashok K.
Ganga, Ranganath T.
Halnor, Dnyaneshwar
Avhad, Ajit
Khan, Mohd Saif
Ghosh, Ayan
Choudhary, Sumer Sanjiv
Yannawar, Anand Namdevrao
Despande, Shubhangi
Patel, Manish
Anne, Krishna Prasad
Bangar, Yogesh
ADVANCED THERAPEUTICS, 2022, 5 (12)
[43] Efficacy and Safety of Upadacitinib in a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2/3 Clinical Study of Patients with Active Ankylosing Spondylitis
van der Heijde, Desiree
Song, In-Ho
Pangan, Aileen
Deodhar, Atul
Van den Bosch, Filip
Maksymowych, Walter P.
Kim, Tae-Hwan
Kishimoto, Mitsumasa
Everding, Andrea
Sui, Yunxia
Wang, Xin
Chu, Alvina D.
Sieper, Joachim
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[44] EFRUXIFERMIN IN COMPENSATED CIRRHOSIS DUE TO NASH/MASH: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2b TRIAL (SYMMETRY)
Harrison, Stephen A.
Neff, Guy W.
Lucas, Kathryn Jean
Rodriguez, Manuel
Wofford, Scott
Benun, Jacques
Rudraraju, Madhavi
Noureddin, Mazen
Su, Yan
Chan, Doreen
Zari, Arian
De Temple, Brittany
Shringarpure, Reshma
Tillman, Erik
Rolph, Timothy P.
Cheng, Andrew
Yale, Kitty
HEPATOLOGY, 2024, 79 (02) : E37 - E39
[45] A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PHASE 3 TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ANAGLIPTIN IN PATIENTS WITH TYPE 2 DIABETES
Yang, H. K.
Lee, S. H.
Min, K. W.
Park, S. W.
Chung, C. H.
Park, K. S.
Choi, S. H.
Song, K. -H.
Kim, D. -M.
Lee, M. -K.
Sung, Y. A.
Baik, S. H.
Kim, I. J.
Cha, B. -S.
Park, J. H.
Ahn, Y. B.
Lee, I. -K.
Yoo, S. -J.
Kim, J. T.
Park, I. B.
Park, T. S.
Yoon, K. -H.
DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 : S149 - S150
[46] Efficacy and safety of cetagliptin as monotherapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial
Ji, Linong
Lu, Jinmiao
Gao, Leili
Ying, Changjiang
Sun, Jiao
Han, Jie
Zhao, Wenhua
Gao, Yunming
Wang, Kun
Zheng, Xin
Xie, Daosheng
Ding, Juping
Zhao, Jiahong
Yu, Qiang
Wang, Tong
DIABETES OBESITY & METABOLISM, 2023, 25 (12): : 3671 - 3681
[47] Dorzagliatin in drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial
Zhu, Dalong
Li, Xiaoying
Ma, Jianhua
Zeng, Jiao'e
Gan, Shenglian
Dong, Xiaolin
Yang, Jing
Lin, Xiaohong
Cai, Hanqing
Song, Weihong
Li, Xuefeng
Zhang, Keqin
Zhang, Qiu
Lu, Yibing
Bu, Ruifang
Shao, Huige
Wang, Guixia
Yuan, Guoyue
Ran, Xingwu
Liao, Lin
Zhao, Wenjuan
Li, Ping
Sun, Li
Shi, Lixin
Jiang, Zhaoshun
Xue, Yaoming
Jiang, Hongwei
Li, Quanmin
Li, Zongbao
Fu, Maoxiong
Liang, Zerong
Guo, Lian
Liu, Ming
Xu, Chun
Li, Wenhui
Yu, Xuefeng
Qin, Guijun
Yang, Zhou
Su, Benli
Zeng, Longyi
Geng, Houfa
Shi, Yongquan
Zhao, Yu
Zhang, Yi
Yang, Wenying
Chen, Li
NATURE MEDICINE, 2022, 28 (05) : 965 - +
[48] The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis
Abdelmalek, Manal F.
Charles, Edgar D.
Sanyal, Arun J.
Harrison, Stephen A.
Neuschwander-Tetri, Brent A.
Goodman, Zachary
Ehman, Richard A.
Karsdal, Morten
Nakajima, Atsushi
Du, Shuyan
Tirucherai, Giridhar S.
Klinger, George H.
Mora, Johanna
Yamaguchi, Masayuki
Shevell, Diane E.
Loomba, Rohit
CONTEMPORARY CLINICAL TRIALS, 2021, 104
[49] Safety of the oral JAK3/TEC inhibitor ritlecitinib (PF-06651600) in patients with alopecia areata: Results from the ALLEGRO phase 2b/3, randomized, double-blind, placebo-controlled trial
King, Brett
Szepietowski, Jacek C.
Farrant, Paul
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB106 - AB106
[50] Safety of Tildrakizumab in Psoriatic Arthritis: An Interim Analysis from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial
Ritchlin, Christopher
Strand, Vibeke
Ballerini, Rocco
Chou, Richard C.
Rozzo, Stephen
Mendelsohn, Alan
Kavanaugh, Arthur
ARTHRITIS & RHEUMATOLOGY, 2019, 71

← 1 2 3 4 5 →